Oncternal Therapeutics, Inc.
ONCT · NASDAQ
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.11 | -0.29 | 0.09 | 0.12 |
| FCF Yield | -177.95% | -28.02% | -27.03% | -20.31% |
| EV / EBITDA | 1.03 | -1.65 | 0.00 | -2.74 |
| Quality | ||||
| ROIC | -92.95% | -55.43% | -37.83% | -30.39% |
| Gross Margin | 0.00% | -636.70% | -964.85% | -2,145.79% |
| Cash Conversion Ratio | 0.82 | 0.68 | 0.89 | 0.70 |
| Growth | ||||
| Revenue 3-Year CAGR | -3.84% | -20.11% | -35.62% | -48.72% |
| Free Cash Flow Growth | -19.43% | 21.73% | -15.87% | -16.43% |
| Safety | ||||
| Net Debt / EBITDA | 1.48 | 0.69 | 0.00 | 0.69 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 34.23 | 91.69 | 176.02 |